Current issue
Archive
Online first
About the Journal
Editorial Office
Editorial Board
Publisher
Editorial Policies
Ethical standards and procedures
Abstracting and indexing
Reviewers
Honorary Reviewers
Subscription
Contact
Most read articles
Instructions for authors
Publication charge
Books and Events
Books
Events
REVIEW PAPER
Usefulness in daily practice of the Systemic Lupus Erythematosus Disease Activity Index 2000 scale and the Systemic Lupus Erythematosus Disease Activity Score index for assessing the activity of systemic lupus erythematosus
1
Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland
2
Student Scientific Circle at the Department of Rheumatology and Connective Tissue Diseases, Medical University, Lublin, Poland
These authors had equal contribution to this work
Submission date: 2024-05-21
Final revision date: 2024-06-10
Acceptance date: 2024-06-20
Publication date: 2024-07-12
Corresponding author
Dorota Suszek
Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University, 8 Jaczewskiego St., 20954 Lublin, Poland, tel. +48 81 724 47 90, fax: +48 81 724 45 15
Chair and Department of Rheumatology and Connective Tissue Diseases, Medical University, 8 Jaczewskiego St., 20954 Lublin, Poland, tel. +48 81 724 47 90, fax: +48 81 724 45 15
Reumatologia 2024;62(3):187-195
KEYWORDS
TOPICS
ABSTRACT
Systemic lupus erythematosus (SLE) is an autoimmune disease characterized by high heterogeneity of clinical manifestations and an uncertain prognosis. Although the mortality rate due to SLE has decreased significantly in recent decades, there is still a need to find good tools to measure disease activity for early detection of exacerbations and treatment planning. Over the decades, more than a dozen disease activity scales/indicators have been developed, with the SLE Disease Activity Index (SLEDAI) being the most popular. More recently, the new SLE Disease Activity Score (SLE-DAS) has been introduced. This paper compares the two methods of assessing SLE activity, and presents the relevance of these scales in pregnant SLE patients and their use in formulating definitions of remission and low disease activity. The results show that the SLEDAI and the SLE-DAS are of comparable value in assessing SLE activity and complement each other.
REFERENCES (49)
1.
Lazar S, Kahlenberg JM. Systemic Lupus erythematosus: new diagnostic and therapeutic approaches. Annu Rev Med 2023; 74: 339–352, DOI: 10.1146/annurev-med-043021-032611.
2.
Pawlak-Buś K, Schmidt W, Dudziec E, Leszczyński P. Current treatment of systemic lupus erythematosus: a clinician’s perspective. Rheumatol Int 2023; 43: 1395–1407, DOI: 10.1007/s00296-023-05306-5.
3.
Panagiotis A, Lambros A. Current treatment approach, emerging therapies and new horizons in systemic lupus erythematosus. Life 2023; 13: 1496, DOI: 10.3390/life13071496.
4.
Zucchi D, Cardelli C, Elefante E, et al. Treat-to-target in systemic lupus erythematosus: reality or pipe dream. J Clin Med 2023; 12: 3348, DOI: 10.3390/jcm12093348.
5.
Castrejón I, Rúa-Figueroa I, Rosario MP, Carmona L. Clinical composite measures of disease activity and damage used to evaluate patients with systemic lupus erythematosus: A systematic literature review. Reumatol Clin 2014; 10: 309–320, DOI: 10.1016/j.reuma.2014.01.012.
6.
Carter LM, Gordon C, Yee CS, et al. Easy-BILAG: a new tool for simplified recording of SLE disease activity using BILAG-2004 index. Rheumatology (Oxford) 2022; 61: 4006–4015, DOI:10.1093/rheumatology/keab883.
7.
Cruciani C, Zen M, Gatto M, et al. Assessment of disease activity and damage in SLE: Are we there yet? Best Pract Res Clin Rheumatol 2023; 12: 101896, DOI: 10.1016/j.berh.2023.101896.
8.
Parra Sánchez AR, van Vollenhoven RF, Morand EF, et al. Targeting DORIS Remission and LLDAS in SLE: A Review. Rheumatol Ther 2023; 10: 1459–1477, DOI: 10.1007/s40744-023-00601-w.
9.
Tselios K, Gladman DD, Urowitz MB. How can we define low disease activity in systemic lupus erythematosus? Semin Arthritis Rheum 2019; 48: 1035–1040, DOI: 10.1016/j.semarthrit.2018. 10.013.
10.
Pitsigavdaki S., Nikoloudaki M, Garantziotis P, et al. Pragmatic targets for moderate/severe SLE and their implications for clinical care and trial design: sustained DORIS or LLDAS for at least 6 months is sufficient while their attainment for at least 24 months ensures high specificity for damage-free progression. Ann Rheum Dis 2024; 12; 83: 464–474, DOI: 10.1136/ard-2023-224919.
11.
Bombardier C, Gladman DD, Urowitz MB, et al. Derivation of the SLEDAI. A Disease Activity Index for Lupus Patients. Arthritis Rheum 1992; 35: 630–640, DOI: 10.1002/art.1780350606.
12.
Stajszczyk M, Majdan M, Kwiatkowska B, et al. Systemic lupus erythematosus in Poland – medical and social aspects of the disease and treatment strategy. Polish Society of Rheumatology, Warsaw 2023. Available at: https://reumatologia.ptr.net.p... (Access: 27.12.2023).
13.
Uribe AG, Vilá LM, McGwin G Jr, et al. The Systemic Lupus Activity Measure-revised, the Mexican Systemic Lupus Erythematosus Disease Activity Index (SLEDAI), and a modified SLEDAI-2K are adequate instruments to measure disease activity in systemic lupus erythematosus. J Rheumatol 2004; 31: 1934–1940.
14.
Gladman DD, Ibañez D, Urowitz MB. Systemic lupus erythematosus disease activity index 2000. J Rheumatol 2002; 29: 288–291.
15.
Arora S, Isenberg DA, Castrejon I. Measures of Adult Systemic Lupus Erythematosus: Disease Activity and Damage. Arthritis Care Res (Hoboken) 2020; 72 Suppl 10: 27–46, DOI: 10.1002/acr.24221.
16.
Carter EE, Barr SG, Clarke AE. The global burden of SLE: Prevalence, health disparities and socioeconomic impact. Nat Rev Rheumatol 2016; 12: 605–620, DOI: 10.1038/nrrheum.2016.137.
17.
Pawlak-Buś K, Leszczyński P. 2022 Systemic lupus erythematosus remission in clinical practice. Message for Polish rheumatologists. Reumatologia 2022; 60: 125–132, DOI: 10.5114/reum.2022.115667.
18.
Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Outcomes in patients with systemic lupus erythematosus with and without a prolonged serologically active clinically quiescent period. Arthritis Care Res (Hoboken) 2012; 64: 511–518, DOI: 10.1002/acr.21568.
19.
Steiman AJ, Gladman DD, Ibañez D, Urowitz MB. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol 2010; 37: 1822–1827, DOI: 10.3899/jrheum.100007.
20.
Floris A, Piga M, Cauli A, Mathieu A. Predictors of flares in systemic lupus erythematosus: preventive therapeutic intervention based on serial anti-dsDNA antibodies assessment. Analysis of a monocentric cohort and literature review. Autoimmun Rev 2016; 15: 656–663, DOI: 10.1016/j.autrev.2016.02.019.
21.
Leilei Y, Bingjie Gu, Xiaoqin W, et al. Association of disease activity with depression and anxiety in systemic lupus erythematosus: A comparison of SLEDAI-2K and SLE-DAS. Rheumatology (Oxford) 2024, DOI: 10.1093/rheumatology/keae070.
22.
Ohmura K. Which is the best SLE activity index for clinical trials? Mod Rheumatol 2021; 31: 20–28, DOI: 10.1080/ 14397595.2020.1775928.
23.
Mikdashi J, Nived O. Measuring disease activity in adults with systemic lupus erythematosus: the challenges of administrative burden and responsiveness to patient concerns in clinical research. Arthritis Res Ther 2015; 17: 183, DOI: 10.1186/s13075-015-0702-6.
24.
Piga M, Chessa E, Morand EF, et al. Physician Global Assessment International Standardisation Consensus in Systemic Lupus Erythematosus: the PISCOS study. Lancet Rheumatol 2022; 4: e441–e449, DOI: 10.1016/S2665-9913(22)00107-2.
25.
Jesus D, Matos A, Henriques C, et al. Derivation and validation of the SLE Disease Activity Score (SLE-DAS): a new SLE continuous measure with high sensitivity for changes in disease activity. Ann Rheum Dis 2019; 78: 365–371, DOI: 10.1136/annrheumdis-2018-214502.
26.
Koo M, Lu MC. Performance of a New Instrument for the Measurement of Systemic Lupus Erythematosus Disease Activity: The SLE-DAS. Medicina (Kaunas) 2023; 59: 2097, DOI: 10.3390/medicina5912209725.
27.
Ramírez Sepúlveda JI, Bolin K, Mofors J, et al. Sex differences in clinical presentation of systemic lupus erythematosus. Biol Sex Differ 2019; 10: 60, DOI: 10.1186/s13293-019-0274-226.
28.
Lai NS, Lu MC, Chang HH, et al. A Comparison of the Correlation of Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) and Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) with Health-Related Quality of Life. J Clin Med 2021; 10: 2137, DOI: 10.3390/jcm10102137.
30.
Jesus D, Larosa M, Henriques C, et al. Systemic Lupus Erythematosus Disease Activity Score (SLE-DAS) enables accurate and user-friendly definitions of clinical remission and categories of disease activity. Ann Rheum Dis 2021; 80: 15681574, DOI: 10.1136/annrheumdis-2021-220363.
31.
Abdelhady EI, Rabie M, Hassan RA. Validity of systemic lupus erythematosus disease activity score (SLE-DAS) for definition of lupus low disease activity state (LLDAS). Clin Rheumatol 2021; 40: 4553–4558, DOI: 10.1007/s10067-021-05803-7.
32.
Buyon JP, Kalunian KC, Ramsey-Goldman R, et al. Assessing disease activity in SLE patients during pregnancy. Lupus 1999; 8: 677–684, DOI: 10.1191/096120399680411272.
33.
Pastore DEA, Costa ML, Parpinelli MA, Surita FG. A Critical Review on Obstetric Follow-up of Women Affected by Systemic Lupus Erythematosus. Rev Bras Ginecol Obstet 2018; 40: 209–224, DOI: 10.1055/s-0038-1625951.
34.
Çetin Ç, Saraç-Sivrikoz T, Ateş-Tıkız M, et al. The correlation between pregnancy, disease activity and adverse pregnancy outcomes in patients with systemic lupus erythematosus. Lupus 2023; 32: 1509–1517, DOI: 10.1177/09612033231208844.
35.
Murata T, Kyozuka H, Fukuda T, et al. Maternal disease activity and serological activity as predictors of adverse pregnancy outcomes in women with systemic lupus erythematosus: a retrospective chart review. Arch Gynecol Obstet 2022; 305: 1177–1183, DOI: 10.1007/s00404-021-06148-x.
36.
Erazo-Martínez V, Nieto-Aristizábal I, Ojeda I, et al. Systemic erythematosus lupus and pregnancy outcomes in a Colombian cohort. Lupus 2021; 30: 2310–2317, DOI: 10.1177/09612033211061478.
37.
Ignacchiti Lacerda M, Costa Rodrigues B, Ramires de Jesús G, et al. The association between active proliferative lupus nephritis during pregnancy and small for gestational age newborns. Clin Exp Rheumatol. 2021; 39: 1043–1048, DOI: 10.55563/clinexprheumatol/xspect.
38.
Larosa M, Costedoat-Chalumeau N, Guettrot-Imbert G, et al. SLE-DAS in the First Trimester of Gestation Predicts Maternal Lupus Flares Later in Pregnancy. Front Pharmacol 2021; 12: 660123, DOI: 10.3389/fphar.2021.660123.
39.
Franklyn K, Lau CS, Navarra SV, et al. Definition and initial validation of a lupus low disease activity state (LLDAS). Ann Rheum Dis 2016; 75: 1615–1621, DOI: 10.1136/annrheumdis-2015-207726.
40.
van Vollenhoven R, Voskuyl A, Bertsias G, et al. A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Ann Rheum Dis 2017; 76: 554–561, DOI: 10.1136/annrheumdis- 2016-209519.
41.
van Vollenhoven RF, Bertsias G, Doria A, et al. DORIS definition of remission in SLE: final recommendations from an international task force. Lupus Sci Med 2021; 8: e000538, DOI: 10.1136/lupus-2021-000538.
42.
Pawlak-Buś K, Schmidt W, Leszczyński P. Remission and low disease activity in Polish patients with systemic lupus erythematosus - real-life, five-year follow-up outcomes. Eur Rev Med Pharmacol Sci 2023; 27: 949–959, DOI: 10.26355/eurrev_202302_31188.
43.
Saccon F, Zen M, Gatto M, et al. Remission in systemic lupus erythematosus: testing different definitions in a large multicentre cohort. Ann Rheum Dis 2020; 79: 943–950, DOI: 10.1136/annrheumdis-2020-217070.
44.
Inês LS, Fredi M, Jesus D, et al. What is the best instrument to measure disease activity in SLE? – SLE-DAS vs Easy BILAG. Autoimmun Rev 2024; 23: 103428, DOI: 10.1016/j.autrev.2023.103428.
45.
Assunção H, Jesus D, Larosa M, et al. Definition of low disease activity state based on the SLE-DAS: derivation and validation in a multicentre real-life cohort. Rheumatology (Oxford) 2022; 61: 3309–3316, DOI: 10.1093/rheumatology/keab895.
46.
Cunha RN, Saraiva L, Jesus D, et al. Predictors of flare in SLE patients fulfilling lupus low disease activity state: a cohort study of 292 patients with 36-month follow-up. Rheumatology (Oxford) 2023; 62: 3627–3635, DOI: 10.1093/rheumatology/kead097.
47.
Shumilova A, Cheldieva F, Reshetnyak T. Miscellaneous conditions associated with SLE LP-118 Assessment of systemic lupus erythematosus activity and remission: SLEDAI-2k or SLE-DAS – which to choose? Lupus Sci Med 2023; 10, DOI: 10.1136/lupus-2023-KCR.214.
48.
Lu MC, Hsu CW, Koo M, Lai NS. Increased risk of hospital admissions in patients with active systemic lupus erythematosus (SLE) classified according to two different SLE disease activity indices: a prospective cohort study. Clin Exp Rheumatol. 2023; 41: 1409–1416, DOI: 10.55563/clinexprheumatol/2z3tyc.
49.
Wang CL, Koo M, Hsu CW, Lu MC. Increased frequency of hospital admissions with active systemic lupus erythematosus disease activity defined by two different disease activity indices: A cohort study. Lupus 2023; 32: 864–872, DOI: 10.1177/09612033231175268.
Copyright: © Narodowy Instytut Geriatrii, Reumatologii i Rehabilitacji w Warszawie. This is an Open Access journal, all articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International (CC BY-NC-SA 4.0) License (https://creativecommons.org/licenses/by-nc-sa/4.0/), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited and states its license.
| eISSN: | 2084-9834 |
| ISSN: | 0034-6233 |
We process personal data collected when visiting the website. The function of obtaining information about users and their behavior is carried out by voluntarily entered information in forms and saving cookies in end devices. Data, including cookies, are used to provide services, improve the user experience and to analyze the traffic in accordance with the Privacy policy. Data are also collected and processed by Google Analytics tool (more).
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
You can change cookies settings in your browser. Restricted use of cookies in the browser configuration may affect some functionalities of the website.
